Action 1672 ASCLETIS PHARMA INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Ascletis Pharma Inc.

Actions

1672

KYG0520K1094

Marché Fermé - Hong Kong S.E.
Autres places de cotation
 10:09:00 03/05/2024 		Varia. 5j. Varia. 1 janv.
1,42 HKD +1,43% Graphique intraday de Ascletis Pharma Inc. +4,41% -2,74%
03/04 Ascletis interrompt les essais de son agoniste du FXR pour la cholangite biliaire, la NASH et le virus de l'hépatite B MT
03/04 Ascletis Pharma Inc. annonce des décisions stratégiques concernant l'agoniste FXR ASC42 CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus
Ascletis Announces Strategic Decisions on FXR agonist ASC42
Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42
Ascletis Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Ascletis Pharma Inc. Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting
Ascletis Pharma Doses First Patient in Phase 3 Clinical Trial of Acne Vulgaris Drug
Ascletis Announces Dosing of the First Patient in Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne
Ascletis Pharma Inc. Announces Dosing of the First Patient in Phase III Clinical Trial of Asc40 (Denifanstat) for Treatment of Acne
Gannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH
Ascletis Pharma's Liver Treatment Reduces Fat in 9 of 10 Participants During Phase 2 Trial
Gannex Announces Positive Interim Results from 52-Week Phase II Clinical Trial of Once-Daily ASC41 Tablet in Patients with Biopsy-Confirmed Non-alcoholic Steatohepatitis
Ascletis Pharma Inc. Announces Positive Interim Results from 52-Week Phase Ii Clinical Trial of Once-Daily Asc41 Tablet in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis
Ascletis Announces Initiation of Phase III Clinical Trial of ASC40 for Treatment of Acne
Ascletis Pharma Gets Nod to Trial Acne Drug
Ascletis Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne
Ascletis Pharma Inc. Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne
Ascletis Pharma Presents Data on Studies for Liver Treatments at US Liver Disease Meet
Ascletis Pharma Publishes Results of Gannex's Fatty Liver Medication
Ascletis Pharma Presents Data in Germany from Phase 2 Study on Anti-Acne Drug
Ascletis Announces Poster Presentation of Phase II Study Topline Results of FASN Inhibitor ASC40 for Treatment of Acne at EADV Congress 2023
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action 1672
  4. Actualités Ascletis Pharma Inc.
  5. Autres langues